Insmed (INSM) Non-Current Assets (2010 - 2026)
Insmed (INSM) posted quarterly Non-Current Assets of $462.7 million for Q1 2026, up 15.66% year-over-year from $400.0 million in Q1 2025, and down 1.63% quarter-over-quarter from $470.4 million in Q4 2025.
Insmed (INSM) Non-Current Assets (2010 - 2026) Analysis & Trends
Insmed's Non-Current Assets history runs 17 years deep, the most recent figure standing at $462.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 15.66% year-over-year to $462.7 million; the TTM figure through Mar 2026 stood at $1.8 billion (up 10.11% YoY), while the FY2025 annual figure was $470.4 million, up 16.55% from the prior year.
- Non-Current Assets for Q1 2026 stood at $462.7 million, down from $470.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $470.4 million in Q4 2025, with the low at $362.7 million in Q3 2022.
- The 5-year median for Non-Current Assets is $398.3 million (2023), against an average of $403.2 million.
- Peak annual rise in Non-Current Assets reached 107.52% in 2022, while the deepest fall reached 5.76% in 2022.
- Insmed's Non-Current Assets stood at $383.1 million in 2022, then advanced by 4.63% to $400.8 million in 2023, then increased by 0.7% to $403.6 million in 2024, then grew by 16.55% to $470.4 million in 2025, then slipped by 1.63% to $462.7 million in 2026.
- Business Quant data shows INSM's Non-Current Assets at $462.7 million in Q1 2026, $470.4 million in Q4 2025, and $428.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 468.65 Mn |
| Mar 31, 2026 | 462.69 Mn |
| Dec 31, 2025 | 470.35 Mn |
| Sep 30, 2025 | 428.93 Mn |
| Jun 30, 2025 | 398.28 Mn |
| Mar 31, 2025 | 400.04 Mn |
| Dec 31, 2024 | 403.57 Mn |
| Sep 30, 2024 | 403.13 Mn |
| Jun 30, 2024 | 391.93 Mn |
| Mar 31, 2024 | 400.37 Mn |
| Dec 31, 2023 | 400.77 Mn |
| Sep 30, 2023 | 398.30 Mn |
| Jun 30, 2023 | 386.72 Mn |
| Mar 31, 2023 | 388.65 Mn |
| Dec 31, 2022 | 383.05 Mn |
| Sep 30, 2022 | 362.65 Mn |
| Jun 30, 2022 | 378.63 Mn |
| Mar 31, 2022 | 397.18 Mn |
| Dec 31, 2021 | 406.47 Mn |
| Sep 30, 2021 | 352.79 Mn |